(Q53088327)

11 May 2018

title

Expression of sclerostin scFv and the effect of sclerostin scFv on healing of osteoporotic femur fracture in rats. (English)

1 reference

11 May 2018

0 references

Qi Yao

1

1 reference

11 May 2018

Jie Ni

2

1 reference

11 May 2018

Yu Hou

3

1 reference

11 May 2018

Lixiang Ding

4

1 reference

11 May 2018

Licheng Zhang

5

1 reference

11 May 2018

Hua Jiang

6

1 reference

11 May 2018

publication date

1 June 2014

1 reference

11 May 2018

Cell Biochemistry and Biophysics

published in

1 reference

11 May 2018

volume

69

1 reference

11 May 2018

issue

2

1 reference

11 May 2018

page(s)

229-235

1 reference

11 May 2018

https://scigraph.springernature.com/pub.10.1007/s12013-013-9787-1

exact match

0 references

cites work

Osteoporosis: now and the future

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

scFv antibody: principles and clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

Phage antibodies: filamentous phage displaying antibody variable domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

Anabolic agents and bone quality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

Targeting sclerostin as potential treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

Sclerostin: current knowledge and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9787-1

10.1007/S12013-013-9787-1

21 January 2018

Identifiers

DOI

1 reference

11 May 2018

PubMed ID

24254971

1 reference

11 May 2018